These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31190787)

  • 1. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
    Celli BR; Navaie M; Xu Z; Cho-Reyes S; Dembek C; Gilmer TP
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1019-1031. PubMed ID: 31190787
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease.
    Gilmer TP; Celli BR; Xu Z; Cho-Reyes S; Dembek C; Navaie M
    COPD; 2019 Apr; 16(2):140-151. PubMed ID: 31215259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators.
    Keshishian A; Xie L; Dembek C; Yuce H
    Clin Ther; 2019 Nov; 41(11):2283-2296. PubMed ID: 31630815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
    Ganapathy V; Stensland MD
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1793-1801. PubMed ID: 28694692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
    Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
    Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends and Factors Associated with Nebulized Therapy Prescription in Older Adults with Chronic Obstructive Pulmonary Disease from 2008 to 2015.
    Singh M; Duarte AG; Hsu ES; Kuo YF; Sharma G
    J Aerosol Med Pulm Drug Deliv; 2020 Jun; 33(3):161-169. PubMed ID: 32017642
    [No Abstract]   [Full Text] [Related]  

  • 7. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
    Chen YJ; Makin C; Bollu VK; Navaie M; Celli BR
    J Med Econ; 2016; 19(1):11-20. PubMed ID: 26357881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of early medication use for COPD: a population-based cohort study.
    Falk J; Dik N; Bugden S
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.
    Navaie M; Celli BR; Xu Z; Cho-Reyes S; Dembek C; Gilmer TP
    Chronic Obstr Pulm Dis; 2019 Oct; 6(4):297-307. PubMed ID: 31483988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
    Hanania NA; Sethi S; Koltun A; Ward JK; Spanton J; Ng D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():117-127. PubMed ID: 30643398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
    Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
    Bloom CI; Elkin SL; Quint JK
    Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC; Stemkowski S; Stanford RH; Tao Z
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA; Waterman LA; Ward J; Gifford AH
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.
    Bishwakarma R; Zhang W; Kuo YF; Sharma G
    Int J Chron Obstruct Pulmon Dis; 2017; 12():477-486. PubMed ID: 28203071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data.
    Baker CL; Zou KH; Su J
    Int J Chron Obstruct Pulmon Dis; 2014; 9():431-9. PubMed ID: 24833898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.